Why the study?
Do low-molecular-weight heparins prevent venous thromboembolism and improve survival in cancer patients compared to other antithrombotics?
Population
Cancer patients at risk of venous thromboembolism
Comparison
Low-molecular-weight heparins vs Other available antithrombotics
Design
Review
Authors
Loading...
LMWH remain an option for VTE prophylaxis in cancer; antitumor survival effect is hypothesis-generating and requires prospective confirmation.
Do low-molecular-weight heparins prevent venous thromboembolism and improve survival in cancer patients compared to other antithrombotics?
Low-molecular-weight heparins offer practical advantages for VTE prophylaxis in cancer patients and may provide additional survival benefits through potential antitumor effects.
Francisco Robert (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: